Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved vandetanib for reimbursement as a monotherapy treatment option for the treatment of patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) that is Rearranged during Transfection (RET) mutation positive.
This is written in the approval document as:
Treatment of medullary thyroid cancer (MTC) in patients with Rearranged during Transfection (RET) mutation positive, unresectable locally advanced or metastatic disease.
Citation
Vandetanib Therapy, 2023, version number 5, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/242vandetanibmonotherapy.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | v::RET | Medullary Thyroid Cancer | Vandetanib |